A novel core-shell nanofiber drug delivery system intended for the synergistic treatment of melanoma

Li Fang Zhu, Yufei Zheng, Jiannan Fan, Yuanfa Yao, Zeeshan Ahmad, Ming Wei Chang

Research output: Contribution to journalArticlepeer-review

59 Citations (Scopus)
270 Downloads (Pure)


Here, we introduce core-shell nanofibers based on chitosan (CS)-loaded poly (ε-caprolactone) (PCL) shell and 5-fluorouracil (5-FU)-loaded Poly(N-vinyl-2-pyrrolidone) (PVP) core for synergistic therapy of melanoma skin cancer. The yielded nanofibers exhibited an average diameter of 503 nm with high drug-encapsulating efficiency and good mechanical properties. Moreover, the burst release of 5-FU significantly inhibited melanoma skin cancer cells (B16F10 cells), and the sustained release of CS exhibited “remedying effects” on normal skin cells (L929 cells) after suffering adverse effects from 5-FU treatment. For the B16F10 cells, the early apoptosis cells increased from 0.8% to 62.2% after being treated with blended films loaded with 5-FU (2 wt%) for 24 h; for the L929 cells, the vital cells increased from 68.9% to 77.0%, and the early apoptosis of stage cells decreased from 12.3% to 10.9% after being treated with blended films with CS (8 wt%) for 24 h. In conclusion, the results introduced in this work can be a promising strategy for cancer treatment and possesses synergism potential to broaden an avenue for chemotherapeutic therapy with minimum adverse effects on normal cells.

Original languageEnglish
Article number105002
JournalEuropean Journal of Pharmaceutical Sciences
Early online date11 Jul 2019
Publication statusPublished (in print/issue) - 1 Sept 2019


  • 5-Fluorouracil
  • Chitosan
  • Controlled release
  • Core-shell nanofiber
  • Skin cancer


Dive into the research topics of 'A novel core-shell nanofiber drug delivery system intended for the synergistic treatment of melanoma'. Together they form a unique fingerprint.

Cite this